Cheryl Gault Sells 2,014 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) COO Cheryl Gault sold 2,014 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $28.93, for a total value of $58,265.02. Following the transaction, the chief operating officer directly owned 169,914 shares in the company, valued at $4,915,612.02. The trade was a 1.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Rapport Therapeutics Trading Up 1.0%

Shares of NASDAQ:RAPP traded up $0.30 on Monday, reaching $30.54. 887,969 shares of the company’s stock were exchanged, compared to its average volume of 339,106. Rapport Therapeutics, Inc. has a twelve month low of $7.73 and a twelve month high of $42.27. The company has a fifty day moving average of $28.15 and a 200-day moving average of $26.65. The company has a market capitalization of $1.46 billion, a price-to-earnings ratio of -11.27 and a beta of 1.51.

Hedge Funds Weigh In On Rapport Therapeutics

Hedge funds have recently modified their holdings of the company. Invesco Ltd. raised its position in shares of Rapport Therapeutics by 69.1% during the 4th quarter. Invesco Ltd. now owns 267,120 shares of the company’s stock valued at $8,104,000 after purchasing an additional 109,136 shares during the period. XTX Topco Ltd purchased a new position in shares of Rapport Therapeutics in the 4th quarter worth approximately $396,000. Vestal Point Capital LP increased its position in Rapport Therapeutics by 16.8% during the fourth quarter. Vestal Point Capital LP now owns 1,110,000 shares of the company’s stock valued at $33,677,000 after acquiring an additional 160,000 shares during the last quarter. Quadrature Capital Ltd purchased a new stake in Rapport Therapeutics in the 4th quarter worth about $268,000. Finally, Perceptive Advisors LLC raised its holdings in shares of Rapport Therapeutics by 66.8% in the fourth quarter. Perceptive Advisors LLC now owns 673,923 shares of the company’s stock worth $20,447,000 after buying an additional 270,000 shares during the period.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on RAPP. Weiss Ratings reissued a “sell (d-)” rating on shares of Rapport Therapeutics in a research note on Thursday, January 22nd. BTIG Research reiterated a “buy” rating and set a $47.00 price target on shares of Rapport Therapeutics in a report on Monday. HC Wainwright increased their price objective on shares of Rapport Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Wall Street Zen upgraded shares of Rapport Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Rapport Therapeutics in a research report on Thursday, January 8th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Rapport Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $50.80.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.